Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612807 | 0.90 | IKBKB (0.44) | IKBKBMAPK8HDAC8CDK1CDK4 | |
| SCHEMBL13638440 | 0.89 | IKBKB (0.43) | IKBKBMAPK8HDAC8CDK1CDK4 | |
| SCHEMBL13638678 | 0.89 | IKBKB (0.42) | IKBKBMAPK8HDAC8CDK1CDK4 | |
| SCHEMBL14612854 | 0.87 | IKBKB (0.42) | IKBKBMAPK8HDAC8CDK1CDK4 | |
| SCHEMBL13638436 | 0.87 | IKBKB (0.42) | IKBKBMAPK8HDAC8CDK1CDK4 | |
| SCHEMBL14612808 | 0.86 | HDAC8 (0.44) | IKBKBMAPK8HDAC8 | |
| SCHEMBL13638679 | 0.85 | IKBKB (0.41) | IKBKBMAPK8CDK1CDK4CCNB1 | |
| SCHEMBL13638478 | 0.85 | IKBKB (0.48) | IKBKBMAPK8CDK4CDK2MAPK9 | |
| SCHEMBL13638584 | 0.84 | KCNH2 (0.47) | IKBKBHDAC8MAPK10 | |
| SCHEMBL3470852 | 0.84 | IKBKB (0.48) | IKBKBPIK3CGPIK3CAPIK3CBMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | IKBKB 2/4885PIK3CG 266/4885PIK3CA 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.